Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia - Wikidata - awgldk - TriplyDB

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

http://www.wikidata.org/entity/Q24599829

about

Altered natural killer cell differentiation in CD34+ progenitors from chronic myeloid leukemia patients Modulation of the cancer cell transcriptome by culture media formulations and cell density The role of FLT3 in haematopoietic malignancies The expression of syndecan-1 is related to the risk of endometrial hyperplasia progressing to endometrial carcinoma Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease Therapeutic targeting of Janus kinases BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19)Chronic myeloid leukemia: reminiscences and dreams Targeting melanoma by small molecules: challenges ahead Network-based approaches in drug discovery and early development Rhomboids, signalling and cell biology Molecular dynamics and protein function.Imatinib and nilotinib inhibit hematopoietic progenitor cell growth, but do not prevent adhesion, migration and engraftment of human cord blood CD34+ cells A novel quantitative kinase assay using bacterial surface display and flow cytometry Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cells Role of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs)Protein kinases--the major drug targets of the twenty-first century?Constitutive Activity in an Ancestral Form of Abl Tyrosine Kinase.A novel BCR-ABL1 fusion gene with genetic heterogeneity indicates a good prognosis in a chronic myeloid leukemia case.From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents.Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Treating adults with acute lymphocytic leukemia: new pharmacotherapy options.Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors.Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia.Chemical genetic screening in the zebrafish embryo.Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo Chronic Myelogenous Leukemia cell growth Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases.Libraries of 2β-(N-substituted piperazino)-5α-androstane-3α, 17β-diols: chemical synthesis and cytotoxic effects on human leukemia HL-60 cells and on normal lymphocytes.Morphological Changes in Bone Marrow Post Imatinib Therapy in Chronic Phase CML: A Follow up Study on Sequential Bone Marrow Aspirates and Biopsies.Selecting the best frontline treatment in chronic myeloid leukemia A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.Bridging the gap between basic and clinical investigation Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.Signaling in leukemia: which messenger to kill?Clinical characteristics and treatment outcome of pediatric patients with chronic myeloid leukemia Jaks and stats as therapeutic targets.Development of inhibitors for protein tyrosine kinases.Chronic myelogenous leukaemia.Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory.

P2860

Q22254246-4E00A960-3702-41D9-A5D0-0864E2ACE5D2 Q24273332-67601E2B-C87B-4725-9D63-96EDEBE3F0C9 Q24319174-4FCD201A-D2C6-4EAB-90A9-C42C5899F4CE Q24603990-C5B30276-C925-4644-9DCA-52D9EA915D6A Q24617270-462C4579-DEBC-4D51-9CE2-7A8F3AFB4E3F Q24658483-39A333B9-D493-4EF5-BF1A-D1482F75E269 Q24685696-215C6124-E9DA-4527-A664-3CBBA84C1071 Q26748769-95E7AE55-2079-42C5-9A42-B7A2F77CF643 Q26824642-793AC0C8-0328-47FF-9266-6231D59F8882 Q26827940-C4B99276-DA82-45FE-A745-C231E1E077AB Q28070034-61114F0E-1BD2-4C7E-A754-1B414C2BBE3A Q28248486-A4D23F14-AB19-4D9D-BB9E-1FD2EFD7C897 Q28484493-7C698F07-2EC5-4559-81BA-95E0AC5AB37C Q28535179-A89ABCCB-013B-41B5-97E2-B895F0C4ED94 Q28545195-27E35571-569F-4C69-8B2F-126D956FBC5C Q28765146-937E9DDC-FDDE-4571-BC82-309EBAE9ACE3 Q29615339-79CC9C92-A7F6-4C3E-8AFD-8B5FF2098EFC Q30009150-11F7FE0C-D6CD-4D53-A305-629AD40EBAC9 Q30152631-62877592-1927-4FA0-90E3-674432728CA4 Q30168082-2C181BF0-AAA6-48FA-99CE-728986F25C59 Q30242015-592BCDF9-9275-4D8B-8B53-CA0454144D1F Q30243925-E923023D-2916-41FC-97FA-688DB8F01348 Q33196126-21ACA023-DFA1-4691-9F61-98678D76072A Q33345047-3D56F924-260E-490E-A474-A71B450B6E16 Q33501994-334CA840-89A5-47B4-B971-C20F084275D0 Q33588245-F5220C81-06DA-4EB5-BCAF-2A061A2B79A1 Q33603379-10F96E66-8BC3-4D11-B872-36EDC9147953 Q33631185-A16A6976-E3F7-4058-A90A-4504D19177B0 Q33688172-523197F8-E5D6-446E-827F-F5B8B2CCF804 Q33741576-84317BB0-BE5D-444A-8B0D-5DF196E2BA9D Q33764253-8B2A43B2-56F7-41AF-9AFA-32F87EDF9223 Q33767209-13E8A7D4-67EF-4BD6-88DD-29EA6C21E4EA Q33774581-4F4873D3-D6D1-4DD4-A5E8-5A113F9D781B Q33903030-59D29C8F-FD12-4985-B352-97894A1583F9 Q33939607-EC2E8E31-CE69-4F1A-A55A-28859B8859AB Q33952848-4854A9DF-78C4-46B2-A286-49B55062C138 Q34071332-BF80C338-6AB2-4856-AE24-EAF22D0CE72B Q34103669-6029DB79-316E-45D2-A317-E5D668952BD3 Q34135279-21E8C3F3-33FE-4621-A734-3B6F97F95675 Q34235845-9E10B21B-37FB-420B-93A5-E3907A03514E

P2860

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

http://www.wikidata.org/entity/Q24599829

description

2000 nî lūn-bûn

@nan

2000 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Lessons learned from the devel ...... r chronic myelogenous leukemia

@ast

Lessons learned from the devel ...... r chronic myelogenous leukemia

@en

Lessons learned from the devel ...... r chronic myelogenous leukemia

@nl

type

label

Lessons learned from the devel ...... r chronic myelogenous leukemia

@ast

Lessons learned from the devel ...... r chronic myelogenous leukemia

@en

Lessons learned from the devel ...... r chronic myelogenous leukemia

@nl

prefLabel

Lessons learned from the devel ...... r chronic myelogenous leukemia

@ast

Lessons learned from the devel ...... r chronic myelogenous leukemia

@en

Lessons learned from the devel ...... r chronic myelogenous leukemia

@nl

P1433

Q24599829-0E213E3C-6B1C-4BA5-BF5F-FAD701F45C44

P1476

Q24599829-E5DF9513-A65D-4026-8959-E2765FDD509A

P2093

Q24599829-7644769F-F2B7-4317-94B2-C3CF25872BA4

Q24599829-F572337D-B9EE-454E-B92F-D562A61BFDD4

P2860

Q24599829-0ABE1D22-BF19-4202-9149-F1C5861827F4

Q24599829-0CE7BA26-CA01-4B42-8BE2-C17AE081F16D

Q24599829-1DCB6C4E-5CCC-4CB6-9FBE-DBCD9564B0A7

Q24599829-2C1A44F4-AC37-43DC-9DFE-F9F4ACA40C42

Q24599829-2FE05A9C-C23D-4B48-AF50-0196B52D4A2E

Q24599829-41803E99-6D2F-4FB9-8E33-8511B8345612

Q24599829-4A4B78E3-57A9-42D9-9411-CCE0D8E3677D

Q24599829-4BE12530-5E36-4A9A-999D-551B81AB3D0F

Q24599829-5290D607-6FEF-4188-BDA7-E509B873D839

Q24599829-5AF1B902-F2E5-466D-8C25-636E7240AAC3

P304

Q24599829-7AD06E31-5A8B-4A13-825A-F92907775EA4

P31

Q24599829-FC4646D5-8306-43AE-BB83-8573B9BED4D4

P3181

Q24599829-D032F79D-9A52-4DB0-AB35-B8BE9D6AED0C

P356

Q24599829-386E3467-A53D-414B-8790-CF6F5426FF87

P407

Q24599829-3D4874E8-E16F-4448-BC8D-7FD7225BB74D

P433

Q24599829-E39665D6-C11A-4A30-8F78-85BD06BCB1C9

P478

Q24599829-920A8433-1E1C-4A7F-9BA3-8FC20B31A50E

P577

Q24599829-6270ED2D-DA97-4835-96A2-47E8DD602B6A

P5875

Q24599829-4B1FBFDA-FE42-456E-B733-F31D4C80F9EA

P698

Q24599829-B5BA7CC2-4AE5-4AF1-931A-B8E45E87586A

P921

Q24599829-0D16B1B6-CAEC-4999-BAA0-EE189A4E9615

P932

Q24599829-6077EDA9-55B9-4EEB-8B15-103199868BB3

P3181

P356

P1433

Journal of Clinical Investigation

P1476

Lessons learned from the devel ...... r chronic myelogenous leukemia

@en

P2093

B J Druker

http://www.w3.org/2001/XMLSchema#string

N B Lydon

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor

Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors

Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia

Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

The structure-based design of ATP-site directed protein kinase inhibitors.

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.

RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.

P304

3-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4308569

http://www.w3.org/2001/XMLSchema#string

P356

10.1172/JCI9083

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P577

2000-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12694129

http://www.w3.org/2001/XMLSchema#string

P698

10619854

http://www.w3.org/2001/XMLSchema#string

P921

P932

382593

http://www.w3.org/2001/XMLSchema#string